Signal Transduction and Molecular Pharmacology Group

Our group, focuses on the molecular pharmacology and mechanism of action of innovative molecular cancer therapeutic agents. There is particular emphasis on exploiting stress and chaperone pathways and also on oncogenic signal transduction pathways as targets for new drugs.

We collaborate with other groups in the Centre for Cancer Drug Discovery and the ICR, particularly with the screening, biology and medicinal chemistry groups, to identify new chemical tools and design potent and selective drug candidates. For example, the group carried out the cellular and molecular pharmacology work to discover the leading HSP90 molecular chaperone inhibitor NVP-AUY922 and the leading PI3 kinase inhibitor GDC-0941, both of which are now showing promising activity in Phase I clinical trials.

We use chemical tools and drugs alongside molecular genetic technologies to identify and validate drug targets as well as predictive and mode of action biomarkers. We employ a combination of hypothesis-driven approaches together with genome-wide screening and chemical library strategies to interrogate cancer biology and discover innovative small molecule agents that exploit the addictions, dependencies and vulnerabilities of cancer cells. This approach is referred to as “drugging the cancer genome”.

We collaborate with clinical colleagues in the Unit, the ICR and The Royal Marsden to support the clinical assessment of new drugs in hypothesis-driven biomarker-rich clinical trials. There is strong emphasis on the use of the “Pharmacological Audit Trail” that was conceptualised by Professor Workman.

Overall, our objective is to improve the lives of cancer patients through the discovery and development of personalised molecular medicines.